StopDown
Funding · 8 June 2026Immuneel Therapeutics₹100 CrCell and gene therapy developerimmuneel.com ↗

Immuneel raises ₹100 Cr in Series B

By · Editor ·

series-bBengaluruFounded 2018
  • Immuneel Therapeutics develops cell and gene therapies for cancer
  • It raised over ₹100 Cr in Series B from Singularity AMC, Rainmatter, and existing investors
  • Funds will scale manufacturing, advance pipeline, and expand into Asia Pacific and Middle East

What happened

  • Immuneel Therapeutics raised over ₹100 Cr in a Series B funding round.
  • New investors Singularity AMC and Rainmatter by Zerodha participated.
  • Existing investors Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also invested.
  • The company will use the funds to scale GMP manufacturing capacity.
  • It will also advance next-gen cell and gene therapy pipeline.
  • A significant portion will go toward commercialisation of Qartemi.
  • Immuneel plans to expand into Asia Pacific and Middle East markets.

Why it matters

  • India's gene therapy sector is growing with startups like Cellogen and Oncare raising funds.
  • China has hundreds of gene therapy companies, while India's biotech boom is recent.
  • Government funding and evolving investor/regulatory ecosystem are driving momentum.
  • CEO cautions long-term success requires manufacturing, supply chains, and GTM strategies beyond science.

The business

  • Immuneel commercialised Qartemi, a CAR-T therapy for Non-Hodgkin Lymphoma.
  • CAR-T therapy modifies a patient's own immune cells to attack cancer.
  • Non-Hodgkin Lymphoma is a blood cancer of the lymphatic system.
  • The company currently treats lymphoma patients in India; leukemia treatment to start soon.
  • Solid tumor programs are in research, not yet in clinic.
  • It operates India's first internationally benchmarked CAR-T platform.
  • Over 100 patients have been treated since commercial launch in late 2024.
  • Immuneel aims to offer therapy at less than 10% of Western cost of $400,000–$500,000 per patient.

The founders

Kiran Mazumdar-Shaw

co-founder, existing investor
  • Co-founder of Immuneel Therapeutics.
  • Also an existing investor in the company.

Kush M Parmar

co-founder
  • Co-founder of Immuneel Therapeutics.

Siddhartha Mukherjee

co-founder
  • Co-founder of Immuneel Therapeutics.

Who put in money

  • Singularity AMC new investor — An asset management company.
  • Rainmatter by Zerodha new investor — An investment arm of Zerodha.
  • Kiran Mazumdar-Shaw existing investor — Co-founder of Immuneel Therapeutics and a prominent biotech entrepreneur.
  • Eight Roads Ventures existing investor — A venture capital firm.
  • F-Prime Capital existing investor — A venture capital firm.

In numbers

₹100 CrFunding raised · 2026
over 100Patients treated · 2024-2026
~$38 MnTotal funding to date · 2026
$400,000-$500,000Western cost per patient

What happens next

  • Scale GMP manufacturing capacity.
  • Advance next-gen cell and gene therapy pipeline.
  • Expand into Asia Pacific and Middle East markets.
  • Commercialise Qartemi further.
  • Pursue clinical co-development partnerships in Australia and Southeast Asia.

Earlier rounds

  • 2024 · extended Series A · ₹100 Cr · led by Taiba Middle East FZ LLC
  • April 2022 · Series A · ~$15 Mn

Up against

CellogenOncare

Words to know

CAR-T therapy
Chimeric Antigen Receptor T-cell therapy: a treatment that modifies a patient's own immune cells to attack cancer cells.
Non-Hodgkin Lymphoma
A type of blood cancer that starts in the lymphatic system.
GMP manufacturing
Good Manufacturing Practice: a system ensuring products are consistently produced and controlled according to quality standards.
Series B
A later-stage funding round for scaling operations, typically after Series A.

The numbers around it

Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
  • Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.

Everything on Immuneel Therapeutics → · All startup news on 8 June 2026 →

Is this Immuneel Therapeutics? Get your “Featured on StopDown” badge →